Kardiovaskuläre Überwachung und Primärprävention bei Krebstherapien

Hatim Seoudy; Derk Frank; Oliver Müller

doi:10.1055/a-2057-1469

Aktuelle Kardiologie, Table of Contents

Aktuelle Kardiologie 2023; 12(04): 272-278
DOI: 10.1055/a-2057-1469

Kurzübersicht

Kardiovaskuläre Überwachung und Primärprävention bei Krebstherapien

Cardiovascular Surveillance and Primary Prevention in Cancer Patients

Hatim Seoudy

¹Klinik für Innere Medizin III (Kardiologie, Angiologie, internistische Intensivmedizin), Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Deutschland (Ringgold ID: RIN15056)

²Standort Hamburg/Kiel/Lübeck, Kiel, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Kiel, Deutschland

,

Derk Frank

¹Klinik für Innere Medizin III (Kardiologie, Angiologie, internistische Intensivmedizin), Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Deutschland (Ringgold ID: RIN15056)

²Standort Hamburg/Kiel/Lübeck, Kiel, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Kiel, Deutschland

,

Oliver Müller

¹Klinik für Innere Medizin III (Kardiologie, Angiologie, internistische Intensivmedizin), Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Deutschland (Ringgold ID: RIN15056)

²Standort Hamburg/Kiel/Lübeck, Kiel, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Kiel, Deutschland

› Author Affiliations

Abstract

Zusammenfassung

Fortschritte bei der Behandlung von Krebserkrankungen haben zu einer erheblichen Verbesserung der Prognose und einer zunehmenden Bedeutung kardiotoxischer Nebenwirkungen infolge einer onkologischen Therapie geführt. In diesem Zusammenhang hat sich die Kardioonkologie als neue Subspezialisierung etabliert. Die Kardioonkologie verfolgt das Ziel, die Prävention und Behandlung kardiovaskulärer Erkrankungen bei Krebspatienten zu verbessern. Die erstmals im Jahre 2022 publizierten ESC-Leitlinien zum Thema Kardioonkologie beinhalten umfassende Empfehlungen zur kardiovaskulären Risikostratifizierung, Überwachung, Diagnose und Primärprävention im Kontext onkologischer Erkrankungen und Therapien.

Abstract

Advances in cancer treatment have led to substantial improvements in long-term outcomes and an increasing burden of cancer therapy-related cardiotoxicity. In response, cardio-oncology has emerged as an important subspecialty which focuses on the prevention and management of cardiovascular disease in cancer patients. The new ESC guidelines on cardio-oncology published in 2022 provide comprehensive guidance on cardiovascular risk assessment, surveillance and primary prevention in the context of cancer and cancer therapy.

Schlüsselwörter

Kardio-Onkologie - Kardiotoxizität - Krebs - kardiovaskuläre Erkrankungen - Prävention - Überwachung

Keywords

cardiotoxicity - cancer - prevention - surveillance - cardiovascular disease - cardio-oncology

Full Text

References

Literatur
1 Lyon AR, López-Fernández T, Couch LS. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229-4361
2 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249
3 Sturgeon KM, Deng L, Bluethmann SM. et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019; 40: 3889-3897
4 Lyon AR, Dent S, Stanway S. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020; 22: 1945-1960
5 Moslehi J, Zhang Q, Moore KJ. Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity. Circulation 2020; 142: 684-687
6 Hahn VS, Zhang KW, Sun L. et al. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection. Circ Res 2021; 128: 1576-1593
7 Zamorano JL, Gottfridsson C, Asteggiano R. et al. The cancer patient and cardiology. Eur J Heart Fail 2020; 22: 2290-2309
8 Dobson R, Ghosh AK, Ky B. et al. BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab. JACC CardioOncol 2021; 3: 1-16
9 Harries I, Liang K, Williams M. et al. Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol 2020; 2: 270-292
10 Saunderson CED, Plein S, Manisty CH. Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging 2021; 22: 383-396
11 Ferreira VM, Schulz-Menger J, Holmvang G. et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018; 72: 3158-3176
12 Mahmood SS, Fradley MG, Cohen JV. et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018; 71: 1755-1764
13 Plein S, Kozerke S. Are We There Yet?: The Road to Routine Rapid CMR Imaging. JACC Cardiovasc Imaging 2021; 14: 1755-1757
14 Lyon AR, Dent S, Stanway S. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020; 22: 1945-1960
15 European Society of Cardiology. ESC Pocket Guidelines App. Accessed May 21, 2023 at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-derivative-products/ESC-Mobile-Pocket-Guidelines
16 Esteban-Fernández A, Carvajal Estupiñan JF, Gavira-Gómez JJ. et al. Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction. Front Cardiovasc Med 2021; 8: 721080
17 Armenian SH, Yang D, Teh JB. et al. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2018; 2: 1756-1764
18 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
19 American College of Cardiology. STOP-CA Trial: Statin Therapy Associated With Reduced Heart Dysfunction From Anthracyclines. Accessed May 21, 2023 at: https://www.acc.org/latest-in-cardiology/articles/2023/03/01/22/45/sat-930am-stop-ca-acc-2023
20 van Dalen EC, Caron HN, Dickinson HO. et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011; 2011: CD003917
21 Handy CE, Quispe R, Pinto X. et al. Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment: Together We Are Stronger. Circulation 2018; 138: 727-734
22 Visseren FLJ, Mach F, Smulders YM. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-3337
23 Porter C, Azam TU, Mohananey D. et al. Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology. JACC CardioOncol 2022; 4: 302-312
24 Tilemann LM, Heckmann MB, Katus HA. et al. Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol 2018; 107: 271-280